Exp Neurobiol 2018; 27(3): 171-180
Published online June 30, 2018
© The Korean Society for Brain and Neural Sciences
Dong Hwan Ho1†, A Reum Je2†, Haejin Lee2, Ilhong Son1,3, Hee-Seok Kweon2*,Hyung-Gun Kim4* and Wongi Seol1*
1InAm Neuroscience Research Center, Sanbon Medical Center, College of Medicine, Wonkwang University, Gunpo 15865, 2Electron Microscopy Research Center, Korea Basic Science Institute (KBSI), Daejeon 34133, 3Department of Neurology, Sanbon Medical Center, College of Medicine, Wonkwang University, Gunpo 15865, 4Department of Pharmacology, College of Medicine, Dankook University, Cheonan 31116, Korea
Correspondence to: *To whom correspondence should be addressed.
Hee-Seok Kweon, TEL: 82-43-240-5440, FAX: 82-42-865-3939
Hyung-Gun Kim, TEL: 82-41-550-3867, FAX: 82-41-551-3866
Wongi Seol, TEL: 82-31-390-2411, FAX: 82-31-890-2414
†These authors contributed equally
Leucine-rich repeat kinase 2 (LRRK2) mutations are the most common genetic cause of Parkinson's disease (PD). LRRK2 contains a functional kinase domain and G2019S, the most prevalent LRRK2 pathogenic mutation, increases its kinase activity. LRRK2 regulates mitochondria morphology and autophagy in neurons. LPS treatment increases LRRK2 protein level and mitochondrial fission in microglia, and down-regulation of LRRK2 expression or inhibition of its kinase activity attenuates microglia activation. Here, we evaluated the direct role of LRRK2 G2019S in mitochondrial dynamics in microglia. Initial observation of microglia in G2019S transgenic mice revealed a decrease in mitochondrial area and shortage of microglial processes compared with their littermates. Next, we elucidated the molecular mechanisms of these phenotypes. Treatment of BV2 cells and primary microglia with LPS enhanced mitochondrial fission and increased Drp1, a mitochondrial fission marker, as previously reported. Importantly, both phenotypes were rescued by treatment with GSK2578215A, a LRRK2 kinase inhibitor. Finally, the protein levels of CD68, an active microglia marker, Drp1 and TNF-α were significantly higher in brain lysates of G2019S transgenic mice compared with the levels in their littermates. Taken together, our data suggest that LRRK2 could promote microglial mitochondrial alteration via Drp1 in a kinase-dependent manner, resulting in stimulation of pro-inflammatory responses. This mechanism in microglia might be a potential target to develop PD therapy since neuroinflammation by active microglia is a major symptom of PD.
Leucine rich-repeat kinase 2 (LRRK2) is a causal gene of Parkinson's disease (PD, [1,2]), which is the second most common neurodegenerative disease. LRRK2 contains functional kinase and GTPase domains. G2019S, the most prevalent LRRK2 familial pathogenic mutant, is known to exhibit increased kinase activity . Most investigations into the pathogenic mechanism of LRRK2 have been focused on neuronal functions because PD is neurodegenerative disease. The studies revealed that LRRK2 regulates vesicle trafficking, autophagy, oxidative stress, neuronal toxicity and mitochondrial dynamics [4,5,6,7,8,9,10,11,12]. However, neuroinflammation with activated microglia has also been implicated in the pathogenesis of neurodegenerative disorders, such as PD, Alzheimer's disease, Huntington's disease, amyotrophic lateral sclerosis and fronto-temporal dementia . LRRK2 expression in microglia is lower than in dopaminergic neurons . However, protein levels of total LRRK2 and active phospho-LRRK2 were significantly increased by LPS treatment activating microglia
Mitochondria dysfunction is widely accepted as one of the pathogenic mechanisms of PD . In fact, other genetic causes of PD such as mutations in Parkin and PINK1 are known to impair mitochondria [21,22]. Other studies also suggested that LRRK2 regulated mitochondrial dynamics and affected mitochondria damages in neuronal cells [12,23,24,25]. Drp1, also known as mitochondrial fission protein Dlp1, is a component of the LRRK2 interactome and is responsible for LRRK2-mediated mitochondria fission in neurons . However, no study examined the effect of LRRK2 on mitochondrial morphology in microglia. Interestingly, LPS stimulations of microglia also increased mitochondrial fission, Drp1 level, production of pro-inflammatory cytokines and ROS as well as kinase activity of LRRK2 [15,16,26,27,28]. In addition, phagocytic activity of macrophages is regulated by Drp1-mediated mitochondrial fission . These results suggest that LRRK2 facilitated neuroinflammatory response in microglia by regulating mitochondrial dynamics.
The following antibodies were used: LRRK2 (N241A/34, NeuroMabs, 75-253), pS935-LRRK2 (UDD210(12), Abcam, 133450), Drp1 (C5, Santa Cruz, 271583), Tom20 (FL-145, Santa Cruz, sc-11415), CD68 (3F103, Santa Cruz, sc70761), TNFα (52B83, Santa Cruz, sc-52746), Iba-1 (Wako, 019-19741), GFAP (Sigma-Aldrich, G3839), β-actin (Santa Cruz, sc-47778), α-tubulin (DM1A, Sigma, T9026), horseradish peroxidase-conjugated goat anti-rabbit or anti-mouse IgG (Jackson ImmunoResearch. 111-035-003 or 115-035-003) and goat anti-rabbit or anti-mouse IgG H&L (Alexa Fluor® 594, Invitrogen, ab150080 or Alexa Fluor® 488, Invitrogen, ab150113).
BV2 murine microglia cells (4×105) were seeded in 35 mm dishes. Next day, the cells were treated with GSK2578215A (hereinafter GSK, 1 µM, Torcris Bioscience) for 30 min followed by LPS (1 µg/ml) treatment for 6 h. Then, the cells was fixed with 4% paraformaldehyde (PFA, Wako) for immunofluorescence analysis or harvested for Western blot analysis. Culture media derived from these BV2 cells and rat primary microglia administrated with the same treatment as BV2 cells, and brain lysates from G2019S transgenic mouse or littermate were used to perform mouse TNFα ELISA (Biolegend) or rat TNFα DuoSet ELISA (R&D systems) according to the sample species and the manufacturer's instruction.
G2019S transgenic (TG) mice [strain B6; C3-Tg (PDGFB-LRRK2*G2019S) 340D jmo/J, stock number 016575, The Jackson Laboratory, ] were housed in a specific pathogen-free facility at Dankook University Animal Facility on a 12:12-h light/dark cycle. Animal experiments were approved by the Institutional Animal Care and Use Committee of Dankook University (DKU-16-035). Animals were provided free access to food and water. TG mice and their normal control littermates were sacrificed by cervical dislocation. Brains were lysed with 1% Triton X-100 and protease inhibitor cocktail (Calbiochem) in phosphate buffered saline (PBS). Lysates were homogenized 10 times using a 17-gauge needle, cooled on ice for 30 min, and centrifuged at 4,000 ×g for 10 min at 4℃. Each supernatant was collected and analyzed by Western blot.
Rat primary microglial cells were isolated from neonatal rats in the p1 age as previously described .
G2019S TG and non-TG mice were anesthetized with pentobarbital and transcardially perfused with PBS and 4% PFA. Striatum was then dissected from each brain and subjected to EM processing as described previously . Tissues were fixed in 2.5% glutaraldehyde in 0.1 M phosphate buffer (pH 7.4) for 2 h at 4℃ and post-fixed with 1% osmium tetroxide on ice for 2 h. Tissues were then embedded in Epon 812 after dehydration in an ethanol and propylene oxide series. Polymerization was conducted using pure resin at 70℃ for two days. Ultrathin sections (70 nm in thickness) were obtained with an ultramicrotome (UltraCut-UCT, Leica, Austria) and collected on 100-mesh copper grids. After staining with 2% uranyl acetate and lead citrate, the sections were examined by transmission electron microcopy (TEM) (Technai G2 Spirit TWIN, FEI, USA) at 120 kV. To quantify mitochondrial number and size, electron micrographs were obtained at a magnification of 8,000× and analyzed blindly using Image J software.
BV2 cells were treated as indicated, fixed and permeablized with 0.1 % Triton X-100 in DPBS for 5 min at RT. After 1 h of blocking with 3 % BSA and 1 % goat serum in DPBS, cells were incubated with Tom20 antibodies in blocking solution for 8 h at 4℃ followed by incubation with Alexa Fluoro 594 secondary antibodies in blocking solution at RT for 2 h with shaking. Hoechst (Thermo Scientific) staining was accomplished during the final DPBS washing step. Cells on inverted cover slip were mounted using Prolong-Gold (Invitrogen). The experiments were repeated in triplicate. Each set of experiments was observed under a Zeiss LS55 confocal microscope and more than five images were randomly obtained in Airyscan mode. In total, 10~12 cells were selected and their mitochondria (n=16~242/cell, total 412~1094) were analyzed. To determine the mitochondria area and elongation, mitochondrial morphology was measured using the Mito-Morphology Macro of Image J software as previously described [33,34]. The RFP channel of cells stained with Tom20 was extracted and converted to 8-bit grayscale, and then inverted. Individual mitochondria were highlighted on the images and analyzed for changes in mitochondrial area and circularity. The mitochondrial circularity was inversed to calculate mitochondrial elongation .
LRRK2 TG and non-TG mice were anesthetized as described above. Their brains were post-fixed in 4% PFA and coronally sliced into 200 µm sections using a vibratome (VT1000A, Leica, Austria). Sections were washed with PBS and treated with 3% hydrogen peroxide to block endogenous peroxidase activity. Sections were then incubated overnight with anti-Iba1 (1:500, Waco) followed by treatment with biotinylated anti-rabbit antibody (1:200, Vector Laboratories). Anti-Iba1 antibody was detected by avidin-biotin-peroxidase complex (Vector Laboratories) followed by incubation with nickel-enhanced 3, 3′diaminobenzidine (DAB, Sigma). To determine the morphological characteristics of Iba1-labeled microglia, images were obtained at 40× objective magnification using an inverted light microscope (CRX41, Olympus, Japan). The process number and length were analyzed manually using Image J software by an unbiased operator.
Harvested sample were loaded on to 11% SDS-PAGE gel or 4~15% gradient pre-cast gel (Bio-Rad) followed by transfer onto nitrocellulose membranes. The remaining steps and densitometric analysis were similar to the methods described previously .
Data derived from Western blots, ELISA, measured mitochondrial fission, and microglial processes were analyzed and imaged with Prism 6.0 (GraphPad). Data are expressed as means±standard error of the mean (SEM). Statistical analyses of data are described in each figure legend.
To investigate whether LRRK2 regulates mitochondrial fission in microglia, we compared the ultrastructure of mitochondria in the microglia of striatum in G2019S TG and control non-TG littermate mice. We confirmed that the mitochondria number was significantly increased in TG, although the total mitochondria area did not change significantly (Fig. 1A~1C). To analyze fission rates in microglia, we compared the average mitochondria areas between TG and control littermates. The average mitochondria area of TG microglia was significantly decreased compared with the non-TG control (Fig. 1D). Previous studies demonstrated shortening and decreased microglial processes in active microglia [36,37]. We observed similar phenotypes (decreased numbers and shortened length of microglial processes) of TG compared with their non-TG littermates (Fig. 2). These results support the notion that G2019S LRRK2 mutation induced microglial activation and mitochondrial fission in microglia
Previous studies revealed that treatment with ligands in microglial activation increased LRRK2 kinase activity in the primary microglia or murine BV2 microglia cell line [15,38]. Furthermore, increased mitochondrial fission by LPS in BV2 was demonstrated in a previous study . To determine whether LRRK2 kinase activity directly affected mitochondrial fission in LPS-stimulated microglia, BV2 cells were treated with LPS alone or LPS and GSK2578215A (GSK, LRRK2 kinase inhibitor), and their mitochondrial morphologies were examined using an immunofluorescence assay. Image analysis revealed that LPS treatment significantly decreased mitochondrial elongation, suggesting reduced mitochondrial length , whereas co-treatment of LPS and GSK significantly diminished the difference (Fig. 3A, B). In addition, LPS treatment reduced mitochondrial area, and co-treatment abrogated the reduction, although without any statistical significance (Fig. 3A, C). The shortening of mitochondria in the LPS-treated BV2 cells is similar to the phenotype observed in neuronal soma in the G2019S TG . These results suggest that LRRK2 regulated mitochondrial morphology in microglia as well as in neuron .
Previous studies reported that LRRK2 regulated Drp1 protein level in neurons , which prompted us to evaluate Drp1 level in microglia. Both BV2 (Fig. 4A~4F) and rat primary microglia cells (Fig. 4G~4L) were treated with LPS alone or LPS and GSK, followed by analysis of Drp1 and Tom20 protein levels. LPS treatment significantly increased the Drp1 level compared with the sample containing vehicle alone or with co-treatment with LPS and GSK whereas the level of Tom20, a mitochondria marker, was relatively similar among samples in both cell types (Fig. 4). The ratio of Drp1 level to Tom20 (Drp1/Tom20) was increased by LPS treatment compared with other samples and, as expected, the difference was more apparent in primary microglia than BV2 cells (Fig. 4E, K). Absence of significant changes in Tom20 levels suggested that the total mass of mitochondria was not significantly altered by either LPS or LPS/GSK treatment (Fig. 4D, J). However, the increased fission rate induced by LPS was reversed by co-treatment with GSK. The western blot with phospho-S935 LRRK2 antibody confirmed inhibition of LRRK2 kinase by GSK as reported previously (Fig. 4B, H, ). We also tested whether LPS mediated cytokine secretion to confirm activation of BV2 cells and primary microglia by LPS. LPS-mediated TNF-α secretion was significantly increased and the increase was almost restored by GSK pretreatment in both cell types (Fig. 4F, L). These data demonstrate that mitochondrial fission up-regulated by LPS stimulation was attenuated by the inhibitor of LRRK2 kinase.
We consolidated the evidence underlying G2019S-mediated neuroinflammation and mitochondrial fission in microglia
Neurodegenerative diseases are often associated with mitochondrial dysfunction and microglial activation. In fact, PD patients show highly activated microglia in substantia nigra and enhanced pro-inflammatory cytokine expression [40,41].
Numerous studies have shown that mitochondrial dysfunction is critical in PD pathogenesis [20,22,42]. Several pathogenic mutations of PD causal genes such as Parkin, PINK-1, DJ-1, and LRRK2 are known to dysregulate mitochondrial function . Treatment of BV2 with rotenone, which is a PD-causing toxin, activated microglia and generated cytokines and ROS  although the phenotypes were not observed in primary microglia . LPS treatment also increased LRRK2 kinase activity in the brains of mice expressing FLAG-LRRK2, and treatment with LRRK2 kinase inhibitor or shLRRK2 ameliorated TNFα release . Therefore, we tested whether LRRK2 regulated microglial mitochondrial function
Drp1 is a critical mediator of neuroinflammatory response . LPS treatment of microglia increased mitochondrial fission, Drp1 protein level and ROS production in BV2 and mouse primary microglia [26,27]. Moreover, down-regulation of Drp1 by shDrp1 reduced mitochondrial fragmentation, cytokine production and ROS production in BV2 .
Our study connects LRRK2 activation and Drp1 activation, two discrete intermediate steps in LPS-mediated neuroinflammation, and suggests a signal transduction pathway from LPS to neuroinflammation via LRRK2-meiated Drp1 activation in microglia. An earlier study reported that LRRK2 phosphorylates Drp1 at T595 and the expression of T595A Drp1 corrects G2019S-mediated mitochondrial fission in neurons  whereas another report suggested LRRK2-mediated phosphorylation of Drp1 at S616 . In addition, inhibition of Drp1 reported to protect neurons in dopaminergic system in an MPTP-mediated PD model , providing additional evidence for toxic mechanism of LRRK2 G2019S. Because functions of phosphorylated Drp1 are various depending on cell types and phosphorylation sites , it is necessary to investigate the effect of LRRK2-mediated phosphorylation of Drp1 on mitochondrial fission in microglia in a future study.
The G2019S TG mouse we used has been originally reported to express G2019S in a neuron-specific manner because the gene was under the CMV E-PDGF-β promoter [30,49]. The original report to study expression of luciferase under the same PDGF-β promoter showed that at least 15 % of cells expressing luciferase are not neurons , leaving a possibility for direct expression of G2019S in microglia of the TG mice. Moreover, neuronal LRRK2 expression increases secretion of α-synuclein  which is able to activate microglia in a paracrine manner . Previous studies reported that damaged neurons activated microglia
We have previously reported that LRRK2 phosphorylates p53 at T304 and T377 residues and the expression of phosphomimic p53 in BV2 cells induces TNFα expression and its release, resulting in neuronal death . The combined evidence derived from our study suggests that G2019S LRRK2 contributed to the progression of PD by altering the physical condition of mitochondria in microglia during the neuroinflammation. In addition, we suggest Drp1 as a missing link between LPS-induced LRRK2 activation and mitochondrial dynamics, both of which have been reported to induce microglial activation [15,16,26]. Furthermore, our data which was summarized in Fig. 6 suggest that LRRK2 kinase inhibitor attenuates pro-inflammatory response by rescuing of mitochondrial dysregulation in microglia. Therefore, Drp1 regulation by LRRK2 kinase in microglia may be one of the pathogenic mechanisms in PD mediated by LRRK2 G2019S mutation, indicating LRRK2 kinase as a promising PD therapeutic target.